December 21, 2016 / 8:54 AM / 8 months ago

BRIEF-Hansa Medical discontinues Phase II study in acquired TTP

Dec 21 (Reuters) - Hansa Medical AB :

* Discontinues its Phase II study in acquired Thrombotic Thrombocytopenic Purpura (TTP)

* Decision follows it's review of initial results from study demonstrating a non-favourable risk benefit profile

* This decision to discontinue study has no impact on Hansa Medical's ongoing studies with IdeS in renal transplantation or planned studies in other autoimmune indications

* Efficient cleaving of anti-ADAMTS13 autoantibodies did not result in a convincing positive effect on activity of ADAMTS13 enzyme Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below